Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC, CSUR) of the Catalan and Spanish Health Systems/Member of ERN-ReCONNET, Hospital Clínic, Barcelona, Catalonia, Spain.
Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC, CSUR) of the Catalan and Spanish Health Systems/Member of ERN-ReCONNET, Hospital Clínic, Barcelona, Catalonia, Spain.
Med Clin (Barc). 2024 Aug;163 Suppl 1:S31-S35. doi: 10.1016/j.medcli.2024.02.011.
The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most severe clinical presentation of the antiphospholipid syndrome (APS). It was first described in 1992 in a group of patients that presented with multiorgan involvement and microangiopathic features of APS. Most of the current knowledge of CAPS comes from the analysis of all cases collected at the "CAPS Registry" that was created in 2000 to perform studies on this condition. Most cases are triggered by a prothrombotic situation that leads to a multiorgan thrombosis and a cytokine storm. The analysis of cases included in the "CAPS Registry" has shown that the triple therapy with anticoagulation, glucocorticoids, and plasma exchange and/or intravenous immunoglobulins is associated to a better prognosis of CAPS. The improvement of the knowledge allowed a decrease from the 50% mortality rate reported in the first series to 25-30% in the most recent publications.
灾难性抗磷脂综合征(CAPS)是一种罕见的危及生命的临床情况,代表抗磷脂综合征(APS)最严重的临床表现。它于 1992 年首次在一组表现为多器官受累和 APS 的微血管病特征的患者中描述。目前对 CAPS 的大部分了解来自于对 2000 年创建的“CAPS 登记处”中收集的所有病例的分析,该登记处旨在对此种情况进行研究。大多数病例是由促血栓形成情况引发的,导致多器官血栓形成和细胞因子风暴。对“CAPS 登记处”中包含的病例的分析表明,抗凝、糖皮质激素和血浆置换和/或静脉注射免疫球蛋白的三联疗法与 CAPS 的更好预后相关。知识的提高使死亡率从第一个系列报告的 50%下降到最近出版物中的 25-30%。